DUBLIN, Ireland--(BUSINESS WIRE)--Feb.
3, 2005--Elan Corporation, plc today announced that
Japan's Patent Office has issued a patent certificate
for Elan's proprietary NanoCrystal(TM) Technology.
Japanese Patent Number 36020546, which expires January
24, 2012, protects intellectual property related to
Elan's NanoCrystal technology.
"This is a significant milestone in the development
of new applications of our NanoCrystal technology
and may facilitate the expansion of our activities
in Japan, one of the world's most significant pharmaceutical
markets. The patent may allow us to work more closely
with Japanese companies to help them develop and commercialise
compounds that exhibit poor water-solubility,"
said Paul Breen, Executive Vice President, Global
Services & Operations, Elan.
products have been commercialised in the U.S. incorporating
NanoCrystal Technology to date, with several additional
product launches anticipated over the next two years.
About Elan's NanoCrystal
may enhance the clinical performance of poorly water-soluble
drugs by transforming them into nanometer-sized particles.
An increasing number of the drug candidates synthesized
each year by pharmaceutical companies are poorly water-soluble.
Many of these potentially innovative drug candidates
are often abandoned because of poor pharmacokinetic
properties including absorption, distribution, metabolism,
and excretion. NanoCrystal technology has the potential
to rescue a significant percentage of these chemical
compounds. The drug in nano-form can be incorporated
into common dosage forms, including tablets, capsules,
inhalation devices, sterile forms for injection, with
the potential for substantial improvements to clinical
performance. Elan's NanoCrystal Technology is protected
by more than 130 U.S. and foreign patents and patent
applications. More information about Elan's NanoCrystal
technology is available at www.elan.com/drugdelivery.
Elan is a neuroscience-based
biotechnology company that is focused on discovering,
developing, manufacturing, selling and marketing advanced
therapies in neurodegenerative diseases, autoimmune
diseases and severe pain. Elan's (NYSE:ELN) shares
trade on the New York, London and Dublin Stock Exchanges.
is a registered trademark owned by Elan Pharma International
Limited Corporation, Ireland
Elan Corporation, plc